Vonoprazan (Voquezna) was noninferior to lansoprazole (Prevacid) for healing patients with erosive esophagitis, and was superior for maintaining healing, a randomized trial showed. In a modified ...
While most potassium-competitive acid blockers demonstrate superior healing rates than proton pump inhibitors (PPIs) in patients with erosive esophagitis, both types of treatment offer relief compared ...
| DelveInsight The gastroesophageal reflux disease market continues to be constrained by a limited number of approved treatment options and persistent unmet needs, particularly among patients who do ...
Credit: Phathom Pharmaceuticals. Voquezna, a potassium-competitive acid blocker, is supplied as 10mg and 20mg tablets. Voquezna ® (vonoprazan) is now available for the treatment of erosive esophagitis ...
The oral potassium-competitive acid blocker (PCAB) vonoprazan was noninferior and superior to the proton pump inhibitor (PPI) lansoprazole for erosive esophagitis, according to results of the phase 3 ...
Los Angeles, CA – New clinical data demonstrated, for the first time in a prospective study, a direct relationship between controlling gastric (or stomach) acid and healing erosive esophagitis caused ...
throat The application is supported by data from the pivotal phase 3 PHALCON-EE trial which compared the efficacy and safety of vonoprazan to lansoprazole in patients with erosive esophagitis. The New ...
BUFFALO GROVE, Ill.--(BUSINESS WIRE)-- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for ...
Please provide your email address to receive an email when new articles are posted on . The FDA has approved Phathom Pharmaceuticals’ Voquezna tablets 10 mg and 20 mg to treat erosive esophagitis, or ...
Gastroesophageal reflux disease (GERD) is one of the most common disorders of the gastrointestinal tract, with a pooled prevalence of 21% in the U.S., accounting for more than 4.6 million ambulatory ...
Phathom Pharmaceuticals' erosive esophagitis drug vonoprazan performed as well as over-the-counter Prevacid in a head-to-head phase 3 clinical trial, potentially teeing up a 2022 application for FDA ...
FLORHAM PARK, N.J., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results